surmount-1 tirzepatide trial obesity without diabetes For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The Effect of tirzepatide in SURMOUNT-1

Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

Eli Lilly said that obesity increases the risk of diabetes and many metabolic diseases, so treating obesity can improve people's health by reducing the chance of developing metabolic diseases and related complications

Personalized Weight Management at Cisne Wellness Many people feel they could benefit from losing a few pounds to improve how they look and feel

In a recent study, participants who took tirzepatide lost an average of 12.4% of their body weight over 72 weeks

Cell autonomous dysfunction and insulin resistance in pancreatic cells